Call for public comments on draft master protocol
A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients

Please provide your feedback to Professor I Longini: ilongini@ufl.edu by Wednesday 4 March, 2020.

Questions for consideration

1. To what extent do you agree or disagree with the objectives and endpoints. If you disagree please propose an alternative approach.
   Comments on the objectives and endpoints:

2. To what extent do you agree or disagree with the study design. If you disagree please propose an alternative approach.
   Comments on the study design:

3. To what extent do you agree or disagree with the study population. If you disagree please propose an alternative approach.
   Comments on the study population:

4. To what extent do you agree or disagree with the measures to minimize bias: randomization and blinding. If you disagree please propose an alternative approach.
   Comments on the measures to minimize bias: randomization and blinding:

5. To what extent do you agree or disagree with the study intervention discontinuation and subject discontinuation/withdrawal. If you disagree please propose an alternative approach.
   Comments on the study intervention discontinuation and subject discontinuation/withdrawal:

6. To what extent do you agree or disagree with the study assessments and procedures. If you disagree please propose an alternative approach.
   Comments on the study assessments and procedures:

7. To what extent do you agree or disagree with the statistical considerations. If you disagree please propose an alternative approach.
   Comments on the statistical considerations: